



## **Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020**

November 3, 2020

DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS<sup>®</sup> genome editing platform, today announced that it will publish financial results for the third quarter of 2020 and provide a business update on Tuesday, November 10, 2020.

### **About Precision BioSciences, Inc.**

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS<sup>®</sup> genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).

### **Investor Contact:**

Alex Kelly  
Chief Corporate Affairs Officer  
[Alex.Kelly@precisionbiosciences.com](mailto:Alex.Kelly@precisionbiosciences.com)